[Skip to Content]
[Skip to Content Landing]
Article
February 1969

Metachromatic LeukodystrophyTreatment With Arylsulfatase-A

Author Affiliations

Cincinnati
From the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati.

Arch Neurol. 1969;20(2):147-153. doi:10.1001/archneur.1969.00480080047005
Abstract

INFANTILE metachromatic leukodystrophy (MLD) is a genetically determined fatal lipidosis, in which sulfatides (cerebroside sulfates) accumulate in various organs but chiefly affect the white matter of the nervous system.1-3 The activity of the enzyme arylsulfatase-A (ASA) is deficient in patients with MLD. Mehl has shown that purified ASA can degrade cerebroside sulfate in vitro,4 and it is postulated that ASA deficiency results in the accumulation of cerebroside sulfate.5 Various forms of therapy have been attempted in an effort to alter the natural course of the disease, but none has been effective.5-8

Replacement of ASA might degrade the accumulated cerebroside sulfate and there by be an effective treatment. This paper describes the results of both intravenous and intrathecal infusion of ASA in a patient with the late infantile form of metachromatic leukodystrophy.

Report of a Case  The boy was born uneventfully on Aug 20, 1963 with

First Page Preview View Large
First page PDF preview
First page PDF preview
×